candida albicans extract

Candida albicans extract is a biological skin-test antigen derived from *Candida albicans*. It is primarily utilized as an FDA-approved diagnostic tool to assess cell-mediated immunity and delayed-type hypersensitivity (DTH) responses. When injected intradermally, the extract elicits a T-cell-mediated (Type IV) hypersensitivity reaction, producing local inflammation and induration that can be measured to evaluate immunocompetence or rule out anergy (e.g., in tuberculosis testing). Developed and manufactured by Nielsen BioSciences, it is marketed under the brand name Candin. Beyond its diagnostic applications, Candida albicans extract is being developed as an intralesional immunotherapeutic agent for the treatment of human papillomavirus (HPV)-induced lesions, such as common warts (*Verruca vulgaris*), where it has successfully completed Phase 3 clinical trials. Additionally, it has been used as a clinical research probe to evaluate neurogenic inflammation and local immune responses in patients with diabetic polyneuropathy and Charcot neuro-osteoarthropathy.

Brand names

Candin

Other names

Candida albicans skin test antigenCandida albicans antigenCandida antigenPurified Candida albicans Antigen